Oregon Health & Science University

Running trials

• Not yet recruiting

  High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years

  NCT07803692· Oregon Health and Science University· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

  NCT07281027· Phase 3· Yale University· Source

• Not yet recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07728188· Phase 3· AbbVie· Source

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  NCT07292298· Phase 2· University of Colorado, Denver· Source

• Not yet recruiting

  Precision T1D Platform - New Therapies for Cardio-Renal Complications

  NCT07594145· Phase 2· Oregon Health and Science University· Source

• Not yet recruiting

  Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

  NCT07795593· Phase 4· University of Michigan· Source

• Not yet recruiting

  Care COMPASS Study

  NCT07904793· Fitbit LLC· Source

• Recruiting

  Deployment of a Novel National Institute of Neurological Disorders and Stroke Clinical, Biomarker, Imaging, and Modifiers (CBI-M) Classification Framework for Emergency Department Patients With Glasgow Coma Scale 15 Traumatic Brain Injury (PIONEER-Prognosis)

  NCT07858266· University of Michigan· Source

• Recruiting

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· Phase 1/2· Daiichi Sankyo· Source

• Not yet recruiting

  Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

  NCT07675408· Fortis Medical Devices Limited· Source

• Recruiting

  A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

  NCT07725796· Phase 1· UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

  NCT07723963· Phase 2/3· Jazz Pharmaceuticals· Source

• Not yet recruiting

  Rethinking Early Airway Clearence Therapies

  NCT07696338· Nicole Hamblett· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

  NCT07332182· Fin-Ceramica Faenza Spa· Source

• Recruiting

  Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

  NCT07569926· Phase 4· Blue Earth Diagnostics· Source

• Recruiting

  An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Phase 2· Yale University· Source

• Recruiting

  Safety and Efficacy of J147 in Acute Ischemic Stroke

  NCT07430917· Phase 2· Abrexa Pharmaceuticals, Inc.· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· Phase 3· Duke University· Source

• Recruiting

  App-Based Certified Diabetes Education Therapy (AB-CDE)

  NCT07282639· Oregon Health and Science University· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Not yet recruiting

  A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

  NCT07293728· Phase 4· Oregon Health and Science University· Source

• Recruiting

  Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07562152· Phase 3· Immuneering Corporation· Source

• Recruiting

  Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

  NCT06980038· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

• Recruiting

  The HOPE Biobank Resource (BMT CTN 2402 HOPE)

  NCT07227155· Medical College of Wisconsin· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

  NCT07600177· Phase 4· Oregon Health and Science University· Source

• Recruiting

  Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

  NCT07521475· Insulet Corporation· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07154290· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI

  NCT07479433· HeartFlow, Inc.· Source

• Recruiting

  Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

  NCT07405645· University of Virginia· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

  NCT07284472· Phase 2/3· Exciva GmbH· Source

• Active, not recruiting

  A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

  NCT07265479· Phase 3· Organon and Co· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  NCT07007559· Phase 2· ALX Oncology Inc.· Source

• Recruiting

  Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT07216443· Phase 2· Orca Biosystems, Inc.· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Opt-In Early Pilot Study

  NCT06908187· Oregon Health and Science University· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

  NCT06811116· Phase 1/2· National Cancer Institute (NCI)· Source

• Enrolling by invitation

  Impact of Anatomy-Based Cochlear Implant Programming on Early Performance

  NCT06734039· Med-El Corporation· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

Showing 50 of 549.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers36 recruiting
• Lung cancer22 recruiting
• Prostate cancer14 recruiting
• Colorectal cancer13 recruiting
• Acute lymphoblastic leukaemia12 recruiting
• Acute myeloid leukaemia12 recruiting
• Pancreatic cancer11 recruiting
• Heart failure10 recruiting
• Parkinson disease10 recruiting
• Ovarian cancer9 recruiting
• Sarcoma9 recruiting
• Cystic fibrosis8 recruiting
• Kidney cancer8 recruiting
• Myelodysplastic syndromes8 recruiting
• Myeloproliferative neoplasms8 recruiting
• Alzheimer disease7 recruiting
• Bladder cancer7 recruiting
• Chronic lymphocytic leukaemia6 recruiting
• Chronic myeloid leukaemia6 recruiting
• Epilepsy6 recruiting
• High blood pressure6 recruiting
• Multiple myeloma6 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Down syndrome5 recruiting
• Endometrial cancer5 recruiting
• Head and neck cancer5 recruiting
• Melanoma5 recruiting
• Neuroendocrine tumours5 recruiting
• Obesity5 recruiting
• Type 1 diabetes5 recruiting
• Type 2 diabetes5 recruiting
• Amyloidosis4 recruiting
• Chronic kidney disease4 recruiting
• Dermatomyositis and polymyositis (myositis)4 recruiting
• Duchenne muscular dystrophy4 recruiting
• Follicular lymphoma4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Metastatic breast cancer4 recruiting
• Myasthenia gravis4 recruiting
• Stroke4 recruiting
• Aortic aneurysm3 recruiting
• Hearing loss3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Osteoarthritis3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Rheumatoid arthritis3 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Frontotemporal dementia2 recruiting
• Huntington's disease2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Lewy body dementia2 recruiting
• Mantle cell lymphoma2 recruiting
• Neuroblastoma2 recruiting
• Obstructive sleep apnoea2 recruiting
• Triple-negative breast cancer2 recruiting
• ANCA-associated vasculitis1 recruiting
• Ankylosing spondylitis1 recruiting
• Aplastic anaemia1 recruiting
• Autism1 recruiting
• Brain aneurysm1 recruiting
• Bronchiectasis1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Glioblastoma1 recruiting
• Haemophilia1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Multiple system atrophy1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Spinal cord injury1 recruiting
• Spinal muscular atrophy1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting
• Vascular dementia1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Recruiting

  Clinical Course Of Disease In Participants With FA-CM

  NCT06865482· Lexeo Therapeutics· Source

• Completed

  Physical Therapy After Endometriosis Excision

  NCT07127783· Oregon Health and Science University· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Completed

  REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

  NCT06788535· Phase 3· Sharmila Dorbala· Source

• Terminated

  Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

  NCT06714591· Phase 1· SystImmune Inc.· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Immunovia, Inc.· Source

• Completed

  Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study

  NCT06490367· Oregon Health and Science University· Source

• Completed

  Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

  NCT06099665· Tempus AI· Source

• Terminated

  A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

  NCT06508489· Phase 1/2· Sanofi· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Duke University· Source

• Completed

  Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

  NCT06422325· Oregon Health and Science University· Source

• Completed

  A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

  NCT06273852· Early phase 1· Pure Biologics S.A.· Source

• Completed

  A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

  NCT05865886· Phase 2· Boehringer Ingelheim· Source

• Withdrawn

  Study of a Gene Therapy Treatment for Hemophilia A

  NCT06297486· Phase 3· Spark Therapeutics, Inc.· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  A Study of CT-868 in Type 1 Diabetes Mellitus

  NCT06062069· Phase 2· Carmot Therapeutics, Inc.· Source

• Completed

  A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

  NCT06088199· Phase 3· Amgen· Source

• Completed

  The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)

  NCT06072859· Oregon Health and Science University· Source

• Completed

  Early Parkinson's Disease Monotherapy With CVN424

  NCT06006247· Phase 2· Cerevance Beta, Inc.· Source

• Completed

  DailyDose Smart Snack Study for T1D on MDI

  NCT05967260· Oregon Health and Science University· Source

• Recruiting

  Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

  NCT05836259· Phase 1/2· Tenaya Therapeutics· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Tandem Diabetes Care, Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  The CARDIO-TTRansform Scintigraphy Sub-study

  NCT06073587· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Terminated

  Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

  NCT05721222· Phase 1/2· Genmab· Source

• Completed

  Two Way Crossover Closed Loop MPC vs Control IQ

  NCT05799781· Oregon Health and Science University· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

  NCT05721573· Phase 2/3· Abcuro, Inc.· Source

• Terminated

  A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

  NCT05787496· Phase 1· NextCure, Inc.· Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

  NCT05219864· Phase 3· Incyte Corporation· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Completed

  Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

  NCT05590585· Phase 4· Regeneron Pharmaceuticals· Source

• Completed

  Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

  NCT05616221· Phase 2· Armata Pharmaceuticals, Inc.· Source

• Terminated

  A Study to Investigate LYL845 in Adults With Solid Tumors

  NCT05573035· Phase 1· Lyell Immunopharma, Inc.· Source

• Completed

  Impella Real-World Surveillance of Patients Using Sodium Bicarbonate

  NCT05820451· Abiomed Inc.· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

  NCT05682170· Phase 1/2· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Source

• Completed

  Observational Study Comparing Home to Office Spirometry

  NCT05285410· Chris Goss· Source

• Completed

  Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

  NCT05436535· Phase 4· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

  NCT05546476· Phase 2· Pfizer· Source

• Completed

  A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

  NCT05524545· Phase 1· ALX Oncology Inc.· Source

• Recruiting

  Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

  NCT05491525· Phase 2/3· Urovant Sciences GmbH· Source

Showing 50 of 275.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke144 works · 13 trials
• Alzheimer disease133 works · 13 trials
• Heart failure130 works · 18 trials
• Parkinson disease82 works · 22 trials
• Prostate cancer73 works · 32 trials
• Melanoma73 works · 21 trials
• Pancreatic cancer58 works · 28 trials
• Colorectal cancer58 works · 35 trials
• Atopic dermatitis (eczema)57 works · 14 trials
• Epilepsy52 works · 15 trials
• Acute myeloid leukaemia41 works · 45 trials
• Ovarian cancer40 works · 26 trials
• Hypertrophic cardiomyopathy35 works · 8 trials
• Sarcoma35 works · 60 trials
• Amyloidosis32 works · 13 trials
• Hearing loss27 works · 4 trials
• Glaucoma27 works · 0 trials
• Ankylosing spondylitis24 works · 5 trials
• Cystic fibrosis22 works · 25 trials
• Type 1 diabetes21 works · 10 trials
• Rheumatoid arthritis21 works · 8 trials
• Bronchiectasis19 works · 6 trials
• Cushing's syndrome19 works · 2 trials
• Insomnia18 works · 2 trials
• Myeloproliferative neoplasms17 works · 24 trials
• Obstructive sleep apnoea17 works · 3 trials
• Hepatitis C16 works · 1 trial
• Long COVID and ME/CFS16 works · 3 trials
• Neuroendocrine tumours16 works · 12 trials
• Congenital heart disease15 works · 0 trials